Metabolism of iron sorbitol and iron dextaran was examied clinically and experimentally by Fe
59-labeled preparation.
The following results were obtained.
1) Circulating blood volume determined with Fe
59-labeled iron dextran preparation coincided with that obtained by dye method.
2) Radioactivity disappeared exponentially from peripheral blood initial several hours after single intravenous injection of Fe
59-labeled iron dextran containing 90 mg of iron (specific activity 4.4 μc/30mg) both in clincal cases and in experimental rabbits. Plasma iron disappearance T/2 in clinical cases was 7-9 hours and 50-140 minutes in experimental rabbits. Thereafter, the radioactivity disappeaed at slower rate.
There was no significant difference of PID between the anemic and the normal both in patints and raddits.
100% of Fe
59 injected was utilized for Hb synthesis 13 to 25 days after single intravenous injection of the preparation in patients with iron deficiency anemia, while in nomal subjects utilization at 25 th day after injecion was around 80%. Similer results were obtained in experimental rabbits.
3) A marked reduction in UIBC was observed during the course of treatment with iron dextran. Although no significant change was found in UIBC following single intraveous injection of 50mg of iron as iron dextran.
4) Radioactivity was deposited mainly in the liver and bone marrow after single intravenous injection with Fe
59-labeled iron dextran in experimetal rabbits, while a larger amount of Fe
59 was deposited in the site of the injection after single intramuscular administration.
In the latter case, high radioactivity was detected in the regional lymph nodes of the injection site. From these results, it was suggested that intramuscularly injeted iron dextran was absorbed via lymphatic system.
5) Radioactivity appeared in peripheral blood rather rapidly following single intramuscular of Fe
59-labeled iron sorbitol preparation, containing 90mg of iron (3.36μc/50mg/ml), and its maximal level was attained by 3-6 hours after the injecton in patients with iron deficiency anemia. Virtually no radioactivity was left in plasma 24 hours after the injection.
About 30% of Fe
59 was excreted to urine.
Utilization of Fe
59 by red blood cell was rapid as compared with the case of iron dextran, and plateau levels of around 70% was attained by 8-10 th day following single injection of Fe
59-labelcd iron sorbitol.
6) More than 30% of the iron was excreted to urine during the course of treatment of iron deficiency anemia with intramuscular injection of iron sorbitol (daily dose of iron injected 100mg).
It was noted that color of urine become dark as amount of the preparation excreted was increased.
Slight but evident toxic effect developed following intramusclar injection of 200 mg of iron as iron sorbitol. Allergic eruption was observed in a patient with iron deficiency anemia. Increase in Hb levels during treatment with iron sorbitol was excellent.
7) In experimental rabbits, more than 60% of Fe
59 injected in urine by 3 rd day after single intramuscular injection of Fe
59-labeled iron sorbitol (Fe 10mg/kg, 3.3μc/50mg/ml). At that time, only 3.5% of Fe
59 was left in the site of injetion. Less amount of Fe
59 was excreted in the urine in anemic rabbits than in normal rabbits, while utilization of Fe
59 by red blood cells was around 25% in anemic rabbits and it was higher than that in normal rabbits. Similar results were obtained following single intravenous injection of Fe
59-labeled iron sorbitol.
Concentration of Fe
59 of lymph nodes was considerably higher than that of other tissues.
It was however evidently lower as compared with that obtained in experimental rabbits injected with Fe
59-labeled iron dextran.
View full abstract